Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin, J. F.
Right arrow Articles by Holroyd, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, J. F.
Right arrow Articles by Holroyd, M.

Stroke, Vol 16, 386-390, Copyright © 1985 by American Heart Association


ARTICLES

Double-blind controlled trial of prostacyclin in cerebral infarction

JF Martin, N Hamdy, J Nicholl, N Lewtas, U Bergvall, P Owen, D Syder and M Holroyd

Thirty-two patients with acute cerebral infarction received either prostacyclin or placebo intermittently for 65 hours. Pulse and blood pressure were not altered by prostacyclin. After infusion there was no change in infarct volume or cerebral blood flow in either group. After normalisation for starting values, age and site of cerebral infarction there was a greater than 10% improvement in speech in the prostacyclin group, but minimal changes in neurological score or disability status. Age is related to neurological score at 14 days after stroke by decreasing improvement by 6.8% for each additional 10 years. This study has not been able to demonstrate that prostacyclin is effective in the treatment of ischaemic stroke, but due to the sample size the chance of proving this statistically (the power) was small. Similarly any conclusion that prostacyclin is not effective may be wrong because of the Type II error probability being high.


This article has been cited by other articles:


Home page
StrokeHome page
K. Uchino, D. Billheimer, and S. C. Cramer
Entry Criteria and Baseline Characteristics Predict Outcome in Acute Stroke Trials
Stroke, April 1, 2001; 32(4): 909 - 916.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
P. W. Duncan, H. S. Jorgensen, and D. T. Wade
Outcome Measures in Acute Stroke Trials : A Systematic Review and Some Recommendations to Improve Practice
Stroke, June 1, 2000; 31(6): 1429 - 1438.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
L. Roberts and C. Counsell
Assessment of Clinical Outcomes in Acute Stroke Trials
Stroke, May 1, 1998; 29(5): 986 - 991.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Lin, T.-N. Lin, W.-M. Cheung, G.-M. Nian, P.-H. Tseng, S.-F. Chen, J.-J. Chen, S.-K. Shyue, J.-Y. Liou, C.-W. Wu, et al.
Cyclooxygenase-1 and Bicistronic Cyclooxygenase-1/Prostacyclin Synthase Gene Transfer Protect Against Ischemic Cerebral Infarction
Circulation, April 23, 2002; 105(16): 1962 - 1969.
[Abstract] [Full Text] [PDF]